In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid
Authors:
- 1 December 1996
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 23 (12) , 1575-1582
Abstract
The purpose of this investigation was to characterise the in vivo chemistry and binding mechanisms of technetium-99m dimercaptosuccinic acid [99mTc(V)DMSA]. Biodistribution was studied in mice by frozen section whole-body autoradiography and microautoradiography in selected tissues. Binding to bone mineral analogues was studied in vitro using various forms of calcium phosphate and hydroxyapatite under varied conditions. Similar studies with99mTc-hydroxymethylene diphosphonate (HDP) were also carried out for comparison. The in vivo stability of99mTc(V)DMSA was monitored by high-performance liquid chromatographic analysis of blood and urine samples taken over 24 h from patients injected with the tracer. Whole-body autoradiography shows that99mTc(V)DMSA has highest affinity for bone (cortical rather than medullary) in mice. Substantial uptake of the tracer was also observed in the kidney (cytoplasm of cortical renal tubular cells). No specific localisation was observed in the liver at either the microscopic or the macroscopic level. While99mTc-HDP bound strongly to calcium phosphates under all conditions,99mTc(V)DMSA binding was inhibited in the presence of phosphate and was stronger at pH 6.0 than at pH 7.4. In non-phosphate buffers, however, the binding of99mTc(V)DMSA remained high across the pH range 4–7.4.99mTc(V)DTVISA binds to calcium phosphates chemically unaltered, and no radioactive species other than the three isomers of99mTc(V)DMSA were detected in blood or urine samples taken from patients up to 24 h after injection.99mTc(V)DMSA is stable in vivo, and no conversion of the complex to other chemical species needs to be invoked to explain its uptake in bone metastases or soft tissue tumour. Bone affinity may be due to reversible binding of the unaltered complex to the mineral phase of bone.Keywords
This publication has 25 references indexed in Scilit:
- Pentavalent 99Tcm-DMSA in bone tumoursNuclear Medicine Communications, 1995
- 67Ga citrate and99mTc(v)-DMSA scintigraphy in a case of maxillary sinus liposarcomaAnnals of Nuclear Medicine, 1993
- Studies on the preparation and isomeric composition of 186Re- and 188Re-pentavalent rhenium dimercaptosuccinic acid complexNuclear Medicine Communications, 1993
- Investigation of two new [99mTc]Tc-HEDP preparations that can be expected to give a better lesion-to-normal-bone uptake ratio when used as bone scanning agentsNuclear Medicine and Biology, 1993
- 13. Modifying renal uptake of pentavalent 99Tcm-DMSA and pentavalent 186Re-DMSA offers potential for tumour-targeted radiotherapy in medullary thyroid carcinoma (MTC)Nuclear Medicine Communications, 1992
- Synthesis and characterization of [186Re]rhenium(V)dimercaptosuccinic acid: A possible tumour radiotherapy agentInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1991
- The role of technetium-99m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroidBritish Journal of Radiology, 1987
- Imaging of Head and Neck Tumors with Technetium(V)-99m DMSA A New Tumor-Seeking AgentClinical Nuclear Medicine, 1985
- The design of a pentavalent 99mTc− dimercaptosuccinate complex as a tumor imaging agentInternational Journal of Nuclear Medicine and Biology, 1985
- Is ECT Imaging with Tc(V)-99m Dimercaptosuccinic Acid Useful to Detect Lung Metastases of Osteosarcoma?Clinical Nuclear Medicine, 1985